close

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular and infectious diseases, and cancer in the United States and Internationally. The company's products include Remodulin (treprostinil sodium) for the treatment of pulmonary arterial hypertension; and CardioPAL SAVI and Decipher Cardiac Monitors for the treatment of cardiac arrhythmias and ischemic heart disease. Its NDA filed products include Inhaled Treprostinil for pulmonary arterial hypertension and Oral Tadalafil for pulmonary hypertension. The company's Phase III products comprise of Oral Treprostinil for pulmonary arterial hypertension; and Phase II products include Beraprost-MR for pulmonary arterial hypertension, 3F8 MAb for neuroblastoma, Oral Treprostinil for Peripheral vascular disease, and CardioPAL SAVI Wireless Cardiac Event Monitors for Cardiac arrhythmias and ischemic heart disease. Its Phase I products include Inhaled Treprostinil for pulmonary arterial hypertension associated with Idiopathic pulmonary fibrosis, Inhaled Treprostinil with AERx Essence for Pulmonary hypertension, 8H9 MAb for Metastatic brain cancer, and Celgosivir for Hepatitis C. The company's pre-clinical products comprise Miglustat for Hepatitis C and Glycobiology Antiviral Agents for Hepatitis C and other infectious diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	46.55
Volume	693837
Volume Avg	892890
52 Week High	70.74
52 Week Low	36.55
PE	12.82
PE (group average)	39
EPS Year	3.67
EPS change Q/Q	64.71%
EPS change Q/Q Yr ago	-20%
EPS change Q/Q next Q est	-74.55%
EPS change Y/Y	-74.18%
REV change Q/Q	-0.54%
REV change Q/Q Yr ago	28.47%
EPS next Q est	1.10
EPS next Y est	4.85
Divident Annual	0.00
Dividend Yield	0%